Black Diamond Therapeutics Inc expected to post earnings of 20 cents a share - Earnings Preview

Black Diamond Therapeutics

05/05/2025 14:43

Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to show a rise in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report revenue of $28 million, according to the mean estimate from 5 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for earnings of 20 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.50‚Äč, above‚Äč its last closing price of $1.78. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.31
-0.28
Beat
11
Sep. 30 2024
-0.38
-0.37
-0.28
Beat
25.1
Jun. 30 2024
-0.38
-0.39
-0.36
Beat
7‚Äč
Mar. 31 2024
-0.42
-0.43
-0.35
Beat
19.5
‚Äč‚ÄčDec. 31 2023
-0.45
-0.47
-0.34
Beat
27
Sep. 30 2023
-0.44
-0.49
-0.45
Beat
7.5‚Äč
Jun. 30 2023
-0.54
-0.54
-0.52
Beat
3
Mar. 31 2023
-0.61
-0.61
-0.57
Beat
6.2

This summary was machine generated May 5 at 13:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)